摘要: Targeted therapies inhibiting the epidermal growth factor receptor (EGFR) have been introduced in treatment of patients with advanced non-small-cell lung cancer (NSCLC). Many inhibitors EGFR developed, targeting either extracellular domain antibodies or intracellular tyrosine kinase binding small molecules. The inhibitor (TKI) gefitinib (Iressa) was first targeted drug to be registered for NSCLC after failure chemotherapy. Given concurrently together platinum combination chemotherapy both TKIs and erlotinib (Tarceva) failed increase activity. Sequential therapy is currently being investigated further. Studies monoclonal antibody cetuximab (Erbitux) combined are ongoing. Side effects molecules mainly skin rash diarrhea, whereas do not give diarrhea. Selection patients, based on molecular markers patient characteristics, has become an important issue further development these drugs, given there activity a relatively group NSCLC. Newer drugs more than one pathway order find broader patients.
cancernetwork.com参考文章(48)
S. Rodenhuis, S. S. Wagenaar, W. J. Mooi, A. J. M. Boot, R. J. C. Slebos, P. C. Van Bodegom, S. G. Evers, J. L. Bos, Incidence and Possible Clinical Significance of K- ras Oncogene Activation in Adenocarcinoma of the Human Lung Cancer Research. ,vol. 48, pp. 5738- 5741 ,(1988)
W.K. (Bill) Evans, Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer Cancer Treatment Reviews. ,vol. 30, pp. 655- 659 ,(2004) , 10.1016/J.CTRV.2004.08.002
C. Huisman, E.F. Smit, G. Giaccone, P.E. Postmus, Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. Journal of Clinical Oncology. ,vol. 18, pp. 3722- 3730 ,(2000) , 10.1200/JCO.2000.18.21.3722
Gee-Chen Chang, Kun-Chieh Chen, Tsung-Ying Yang, Ming-Chang Yin, Ching-Pei Lin, Benjamin Ing-Tiau Kuo, Jeng-Yuan Hsu, Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status. Investigational New Drugs. ,vol. 23, pp. 73- 77 ,(2005) , 10.1023/B:DRUG.0000047108.39129.7C
Neil A Reynolds, Antona J Wagstaff, Cetuximab: in the treatment of metastatic colorectal cancer. Drugs. ,vol. 64, pp. 109- 121 ,(2004) , 10.2165/00003495-200464010-00007
Pasi A. Jänne, Sarada Gurubhagavatula, Beow Y. Yeap, Joan Lucca, Patricia Ostler, Arthur T. Skarin, Panos Fidias, Thomas J. Lynch, Bruce E. Johnson, Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, ‘Iressa’) on an expanded access study Lung Cancer. ,vol. 44, pp. 221- 230 ,(2004) , 10.1016/J.LUNGCAN.2003.12.014
Athanassios Argiris, Namrata Mittal, Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer Lung Cancer. ,vol. 43, pp. 317- 322 ,(2004) , 10.1016/J.LUNGCAN.2003.10.010
Aruna Kommareddy, Margaret A Coplin, Feng Gao, Danelle Behnken, Edie Romvari, William Read, Ramaswamy Govindan, Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience. Lung Cancer. ,vol. 45, pp. 221- 225 ,(2004) , 10.1016/J.LUNGCAN.2004.01.022
D. M. Parkin, F. Bray, J. Ferlay, P. Pisani, Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians. ,vol. 55, pp. 74- 108 ,(2005) , 10.3322/CANJCLIN.55.2.74
Joan H. Schiller, David Harrington, Chandra P. Belani, Corey Langer, Alan Sandler, James Krook, Junming Zhu, David H. Johnson, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England Journal of Medicine. ,vol. 346, pp. 92- 98 ,(2002) , 10.1056/NEJMOA011954